Clinical trials located in

Norwich

Norwich city is located in United Kingdom. Currently, 10 clinical trials are being conducted in this city.

Norwich, a city in the United Kingdom, boasts a rich history dating back over 900 years. Known for its well-preserved medieval architecture, Norwich has more medieval churches (31) than any other city in England outside London. It was England’s first UNESCO City of Literature, reflecting its vibrant literary heritage and thriving contemporary writing scene. The city’s market, operating since the 11th century, is among the oldest and largest outdoor markets in the country. Norwich also played a significant role in the woolen cloth industry during the Middle Ages, contributing to its prosperity.

  • CT-EU-00035264

    Acalabrutinib, venetoclax and rituximab combination for newly diagnosed mantle cell lymphoma

    This clinical trial explores a new drug combination for treating mantle cell lymphoma in patients who have not received prior treatments. The study involves acalabrutinib, venetoclax, and rituximab (AVR) and aims to determine their effectiveness in achieving a minimal residual disease-negative complete response after 13 cycles of treatment. Patients achieving this response will be randomly assigned to continue acalabrutinib or enter observation. The study’s goal is to assess the efficacy and safety of the AVR combination in newly diagnosed mantle cell lymphoma patients.

    • Acalabrutinib
    • Rituximab
    • Venetoclax
  • New potential drug evaluation in cholestatic pruritus

    This study aims to assess the effectiveness of the potential new drug-EP547 in alleviating cholestatic pruritus among individuals aged 18 to 80 with Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis (PSC). Inclusion criteria involve documented diagnoses of PBC or PSC, the presence of moderate to severe pruritus, and acceptance of specific anti-pruritic and anti-cholestatic medications. Exclusion criteria include pruritus unrelated to PBC or PSC, a history of liver transplantation, cirrhosis, alternative liver diseases, secondary sclerosing cholangitis, significant strictures or biliary stents, small bowel resection, and certain laboratory results indicating ineligibility.

    • EP547- new potential medication for cholestatic and uremic pruritus
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Evaluating the long-term effects of glepaglutide on Short Bowel Syndrome

    The study focuses on glepaglutide’s long-term safety and effectiveness in treating Short Bowel Syndrome (SBS). It examines how different doses, given weekly, help manage SBS, aiming to enhance the quality of life and reduce dependence on parenteral support. The study is pivotal in offering sustainable treatment options for SBS patients.

    • glepaglutide
  • Testing astegolimab’s effectiveness in chronic obstructive pulmonary disease patients

    A clinical research study is being conducted to examine the efficacy and safety of a novel treatment known as astegolimab in the management of Chronic Obstructive Pulmonary Disease (COPD). The study is particularly focused on individuals with a history of COPD who are either current or former smokers and have experienced frequent exacerbations. Within the scope of this study, astegolimab’s therapeutic potential is being compared to that of a placebo. Participants enrolled in the trial will be administered the study medication at intervals of either every 2 or 4 weeks. Key parameters under evaluation include the frequency of COPD exacerbations, variations in the quality of life of the participants, and changes in lung function over the course of the study. The study aims to contribute valuable data to medical research, particularly in understanding the treatment dynamics of astegolimab in COPD management.

    • Astegolimab
  • Testing the efficacy of teclistamab vs other drugs for relapsed or refractory multiple myeloma treatment

    The study is evaluating a treatment for a blood cancer known as multiple myeloma. Two different treatments are being compared to assess their effectiveness in both slowing down the disease and minimizing side effects. The first treatment involves a single medicine called teclistamab, while the second offers a choice between two combinations of multiple medicines (either PVd – pomalidomide, bortezomib, dexamethasone or Kd – carfilzomib, dexamethasone). Both treatments have been previously administered to individuals with similar conditions. Individuals who have undergone prior treatment, including the use of an anti-CD38 monoclonal antibody and lenalidomide, but experienced a recurrence or lack of resolution of the disease, are eligible to participate in this study. The objective is to determine the duration it takes for the disease to progress under different treatments. Additionally, the study will monitor changes in health and potential medication-related issues through regular check-ups.

    • Carfilzomib
    • Pomalidomide
    • Teclistamab
    • Dexamethasone
    • Bortezomib
  • Testing the efficacy and safety of a new drug for knee osteoarthritis pain

    This study is testing a new drug called GSK3858279 for adults suffering from moderate to severe knee joint pain. The main goal is to determine what is the best, safe and effective dose to administer. Participants will be asked to rate their daily knee pain on a scale of 0 to 10, with 0 being no pain and 10 being the worst pain imaginable. This weekly average score will help us understand better. A questionnaire called WOMAC will also be used to understand the overall health and function of the knees and joints, especially in terms of pain, stiffness and functionality. They will also be rated on a scale of 0 to 10. Any side effects, serious side effects, and specific side effects associated with the drug and medical conditions will also be considered. Finally, the science behind the drug’s effects on pain will be analyzed using several measures.

    • GSK3858279- new potential medication for chronic pain associated with osteoarthritis
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in United Kingdom:

.